However the biphenyl/ethylenediamine/Cl osmium analogue was subsequently found to be inactive in vivo in a mammary carcinoma model. 6 The introduction of XY = azopyridine, a strong π-acceptor, as the N,N-chelating ligand has a remarkable effect on the reactivity, especially when Z = 8 We have now investigated the activity of this complex in vivo versus HCT116 human colon cancer xenografts and the distribution of osmium in plasma and tissues. Further insight into the mechanism of action of 1 was obtained from studies of its redox potential, its ability to 4 generate Reactive Oxygen Species (ROS) in cells, and the ability of L-buthioninesulfoximine (L-BSO), a specific inhibitor of γ-glutamyl-cysteine synthetase known to reduce intracellular thiol levels, 9 to enhance the cytotoxicity of the complex.
Results and discussion
First we studied the anticancer efficacy of complex 1 in vivo versus the subcutaneously implanted HCT-116 xenograft model, when administered as a single intravenous injection at its maximum soluble dose of 40 mg/kg. The agent had negligible toxicity, with an observed maximum weight loss well within the normal limits. Complex 1 was seen to induce a statistically significant tumour growth delay in the HCT-116 model compared to the untreated control (p<0.01), and positive control compound, the standard agent cisplatin (p<0.05) ( Fig. 1 and Table 1 ). The lack of toxicity seen, combined with the favourable tumor distribution reported below, would suggest that there is significant scope to administer this compound on a repeat-dose schedule to enhance its therapeutic ability.
Next we investigated the plasma and tissue distribution of osmium after administration of 1 in vivo, in HCT116 xenograft-bearing mice.The distribution of 1 was analysed in the liver, kidneys, tumour, lungs and plasma, 5, 60 and 240 min after administration. The results are shown in Table 2 and Figure S1 . Osmium was detected in the tumour and all tissues over the time period of analysis, whilst amounts of osmium in the plasma were surprisingly low after just 5 min, suggesting a large volume of distribution or high level of tissue distribution.
Complex 1 is relatively inert. For example, it does not readily undergo hydrolysis in aqueous solution or bind to DNA bases, unlike chlorido diamine Os II arene complexes. 
Conclusion
In conclusion, we have demonstrated that the organometallic osmium arene azopyridine complex 1, which has nanomolar activity in vitro in a panel of human cancer cell lines, 8 exhibits acivity in vivo against HCT116 human colon cancer xenografts in mice, with negligible toxicity. This appears to be the first demonstration of significant anticancer activity in vivo for organometallic half-sandwich osmium complexes. Studies on the plasma, tumor and normal tissue distribution of 1 suggest that there is scope to optimize the therapeutic activity using multiple-dose schedules without the risk of off-target toxicity. 
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